Journal profile · ONCOLOGY
Blood Cancer Journal
ISSN 2044-5385 · Springer Nature · ENGLAND · Founded 2011
Blood Cancer Journal: CAS Zone 1 · Medicine (2025 upgraded edition, Top journal); impact factor 13.76; fully open access; APC about USD 5,490; median 109 days to acceptance (113 articles, last 24 months); community-reported acceptance: easy; 230 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Blood Cancer Journal is published by Springer Nature and is in Zone 1 of Medicine in the CAS Journal Ranking (2025 upgraded edition, Top journal). By OpenAlex counts of its recent articles, its largest topics are Multiple Myeloma Research and Treatments, Acute Myeloid Leukemia Research and Lymphoma Diagnosis and Treatment, together about 34.9% of its articles. Its main subfields are Hematology. (generated from OpenAlex topic counts and CAS ranking data)
Publishes high quality articles about hematologic malignancies and related disorders. World's leading voices form the expert editorial team, that offers rapid turnaround times. Open access publication ensures that your work is easily discovered, accessed, and shared.
From the journal's Aims & Scope
Research area (LetPub): ONCOLOGY
Main research topics OpenAlex counts of recent articles; shares are approximate
- Multiple Myeloma Research and TreatmentsMedicine13.9%
- Acute Myeloid Leukemia ResearchMedicine12.1%
- Lymphoma Diagnosis and TreatmentMedicine8.8%
- Chronic Lymphocytic Leukemia ResearchMedicine8.2%
- Myeloproliferative Neoplasms: Diagnosis and TreatmentMedicine7.6%
- Protein Degradation and InhibitorsBiochemistry, Genetics and Molecular Biology6.8%
- Chronic Myeloid Leukemia TreatmentsMedicine6%
- Acute Lymphoblastic Leukemia researchMedicine4.6%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Hematology | Zone 1 |
| Minor | Oncology | Zone 1 |
Top journal: yesReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Oncology | Zone 1 |
| Minor | Hematology | Zone 1 |
Top journal: yesReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Hematology | Zone 1 |
| Minor | Oncology | Zone 1 |
Top journal: yesReview journal: no
Database indexing
SCIEScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
Web of ScienceMEDLINEPubMedPublisher website
Other: Google Scholar
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 13.76LetPub ·
- Impact factor (publisher) 2025
- 13.8Publisher website ·
- 5-year impact factor (publisher) 2025
- 14Publisher website ·
- CiteScore 2026-06
- 16.2LetPub ·
- SJR 2026-06
- 4.31LetPub ·
- SNIP 2026-06
- 2.73LetPub ·
- h-index
- 37LetPub ·
- h-index
- 111OpenAlex ·
- i10-index
- 1,407OpenAlex ·
- 2-year mean citedness
- 7.87OpenAlex ·
- Self-citation rate
- 3.6%LetPub ·
- Share of gold OA articles
- 100%LetPub ·
Volume
- Articles per year
- 105LetPub ·
- Downloads per year (publisher) 2025
- 4,490,823Publisher website ·
Articles by year OpenAlex count · 2,219 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 184 | 184 | 122 |
| 2025 | 230 | 230 | 1,245 |
| 2024 | 224 | 224 | 3,652 |
| 2023 | 194 | 194 | 4,218 |
| 2022 | 173 | 173 | 4,975 |
| 2021 | 203 | 203 | 11,617 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
109 daysMedian, submission to acceptance · P25–P75 76 days – 140 days
- Acceptance to online
- median 16 days (113 articles)
- Submission to online
- median 122 days
- Sample
- 113 articles with submission and acceptance dates (466 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- over 12 weeksLetPub ·
- Average acceptance (community reports)
- EasyLetPub ·
- Submission to publication (journal-reported)
- about 14 weeksDOAJ ·
- Peer review
- Single anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | EUR 4,390 / USD 5,490 / GBP 3,690 | Yes | CC BY, CC BY-NC-ND | |
| OpenAlex | USD 5,290 / EUR 4,190 / GBP 3,590 | — | — | |
| LetPub | GBP 3,390 / USD 4,990 / EUR 3,890 | Yes | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Profile
Publication details and official links
- Publisher
- Springer Nature
- Country or region
- ENGLAND
- Language
- English
- Founded
- 2011
- ISSN
- 2044-5385
- Official links
- Journal homepage ↗DOAJ
- Submission system ↗LetPub
- Author guidelines ↗DOAJ
- Aims & Scope ↗DOAJ
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗DOAJ
- Editorial board ↗DOAJ
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about Blood Cancer Journal
What CAS zone is Blood Cancer Journal in?
In the 2025 upgraded edition of the CAS Journal Ranking, Blood Cancer Journal is in Zone 1 of Medicine, and in Zone 1 of the minor category Hematology / Oncology; it is a Top journal. In the 2026 Xinrui edition it is in Zone 1 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Blood Cancer Journal?
The latest impact factor listed by LetPub is 13.76; CiteScore 16.2, h-index 111.
How long does peer review take at Blood Cancer Journal?
Based on the dates recorded on 113 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 109 days (interquartile range 76–140 days); authors report an average review time of over 12 weeks; the community-reported acceptance is “Easy”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Which databases index Blood Cancer Journal?
According to LetPub and DOAJ records, Blood Cancer Journal is indexed in SCIE, Scopus and DOAJ. The journal's website also lists Web of Science, MEDLINE and PubMed; that list has not been checked against each database.
Is Blood Cancer Journal open access, and what is the APC?
Blood Cancer Journal is a fully open-access journal. APC about USD 5,490.
Sources and updates
The facts on this page come from LetPub, OpenAlex, DOAJ, Publisher website; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .